Journals By Industry - Hormones, Substitutes & Antagonists

NEW YORK -- Levi & Korsinsky is investigating potential claims on behalf of purchasers of Columbia Laboratories Inc. ("Columbia Labs" or the "Company") (Nasdaq: CBRX) securities concerning possible violations of federal securities laws....

DUBLIN -- Research and Markets (http://www.researchandmarkets.com/research/dc66aa/osteoporosis_thera) has announced the addition of GlobalData 's new report "Osteoporosis Therapeutics - Pipeline Assessment and Market Forecasts to 2018" to their offering. The Osteoporosis Therapeutics Market is...

According to plaintiff's attorney Geoffrey N. Fieger, Dr. Andrew Jay Halperin should have known that Kimberly VanSlembrouck's baby was going to be too big to risk a vaginal birth, and he should have...

NEW YORK -- Forest Laboratories, Inc. (NYSE: FRX), an international pharmaceutical manufacturer and marketer, today announced that reported earnings per share were $1.04 in the third quarter of fiscal 2012. Reported earnings per...

EXTON, Pa. -- BioTrends Research Group, LLC has released findings from the LaunchTrends([R]): Zytiga report, the first in a three-wave series. The study was conducted with 106 U.S. urologists and medical oncologists about...

Novel Hormone Identified that Augments Brown Fat, Increases Energy Expenditure, and Reduces Obesity and Insulin Resistance BOSTON -- Ember Therapeutics, Inc., a company harnessing breakthroughs in brown fat biology and insulin sensitization to...

A $28 million award of punitive damages was not unconstitutionally excessive in a product liability case brought by a woman who contracted breast cancer after taking hormone replacement therapy drugs, a Pennsylvania appellate...

ROCKVILLE, Md. -- Trophogen Inc., a biotechnology company developing hormone and related growth factor analogs for human infertility, animal superovulation, and human cancers together with Advanced BioScience Laboratories Inc. (ABL), a biomedical contract...

Evidence of Wyeth's marketing campaign for "off-label" Prempro uses was admissible in a product liability case brought by a woman who contracted breast cancer after taking the drug, a Pennsylvania appellate court has...

ROCKVILLE, Md. -- RegeneRx Biopharmaceuticals, Inc. (OTC Bulletin Board: RGRX) ("the Company" or "RegeneRx") today announced that it has been issued a patent from the U.S. Patent and Trademark Office claiming methods for...

SOUTH SAN FRANCISCO, Calif. -- KAI Pharmaceuticals, Inc., a privately held drug discovery and development company, today announced initiation of patient enrollment in the second Phase 2 study of KAI-4169, a novel pharmaceutical...

ROCKVILLE, Md. -- RegeneRx Biopharmaceuticals, Inc. (OTC Bulletin Board: RGRX) ("the Company" or "RegeneRx") announced today that it has received the clinical study report for its recently completed Phase 2 clinical trial evaluating...

BEDMINSTER, N.J. -- NPS Pharmaceuticals, Inc. (NASDAQ: NPSP) will present at the 30th Annual J.P. Morgan Healthcare Conference in San Francisco on Thursday, January 12, 2012 at 10:30 a.m. PT. The presentation will...

DUBLIN -- Research and Markets (http://www.researchandmarkets.com/research/161b3e/growth_hormone_def) has announced the addition of GlobalData's new report "Growth Hormone Deficiency Global Clinical Trials Review, H2 2011" to their offering. GlobalData's clinical trial report, "Growth Hormone Deficiency...

NEW YORK -- Synergy Pharmaceuticals, Inc. (Nasdaq: SGYP, SGYPU, SGYPW),a developer of new drugs to treat gastrointestinal disorders and diseases, announced today the successful outcome of the Oral Hearing held December 14, 2011...

PALO ALTO, Calif. -- Affymax, Inc. (Nasdaq: AFFY) today announced that it will webcast an analyst briefing on Tuesday, January 10 at 7:15 a.m. PT. During the event, Affymax management will provide a...

JACKSONVILLE, Fla. -- A new website www.ThyroidAwareness.com is being launched in conjunction with January being Thyroid Awareness Month. The website is presented in a blue paisley theme by the American Association of Clinical...

LEXINGTON, Mass. & SYDNEY -- GI Dynamics, Inc. (ASX: GID) today announced the transition of the EndoBarrier([R]) Gastrointestinal Liner (the EndoBarrier), a novel, non-surgical device for the treatment of type 2 diabetes and/or...

Company Starts Clinical Studies with Its Oral CYP17 Lyase Inhibitor for the Treatment of Castration-Refractory Prostate Cancer RESEARCH TRIANGLE PARK, N.C. -- Viamet Pharmaceuticals, Inc., announced today that dosing has begun in a...